TY - JOUR
T1 - Inducible expression of vascular endothelial growth factor in adult mice causes severe proliferative retinopathy and retinal detachment
AU - Ohno-Matsui, Kyoko
AU - Hirose, Akira
AU - Yamamoto, Satoru
AU - Saikia, Jina
AU - Okamoto, Naoyuki
AU - Gehlbach, Peter
AU - Duh, Elia J.
AU - Hackett, Sean
AU - Chang, Michelle
AU - Bok, Dean
AU - Zack, Donald J.
AU - Campochiaro, Peter A.
N1 - Funding Information:
Supported by the National Eye Institute (grants EY05951, EY12609, EY00444, EY0331, and K08 EY13420 to P. G. ); Research to Prevent Blindness (core grant P30EY1765 ), a Lew R. Wasserman Merit Award (to P. A. C.), a Career Development Award (to D. J. Z.), and an unrestricted grant; the Foundation Fighting Blindness, the Ruth and Milton Steinbach Foundation, the Juvenile Diabetes Research Foundation (to P. G.), Michael Panitch, and Dr. and Mrs. William Lake. P. A. C. is the George S. and Dolores Dore Eccles Professor of Ophthalmology and Neuroscience. D. B. is the Dolly Green Professor of Ophthalmology at UCLA.
PY - 2002
Y1 - 2002
N2 - Transgenic mice with vascular endothelial growth factor (VEGF) driven by the rhodopsin promoter (rho/VEGF mice) develop neovascularization that originates from the deep capillary bed of the retina and grows into the subretinal space. In rho/VEGF mice, VEGF expression in photoreceptors begins between postnatal days 5 and 7, the period when the deep capillary bed is developing. An important question is whether or not the developmental stage of the deep capillary bed is critical for occurrence of neovascularization. Also, although rho/VEGF mice are extremely useful for the study of ocular neovascularization, there are some applications for which the early onset of VEGF expression is a disadvantage. In this study, we used the reverse tetracycline transactivator (rtTA) inducible promoter system coupled to either the rhodopsin or interphotoreceptor retinoid-binding protein (IRBP) promoter to control the time of onset of VEGF transgene expression in photoreceptors. In the absence of doxycycline, adult double-transgenic rho/rtTA-TRE/VEGF or IRBP/rtTA-TRE/VEGF mice showed little VEGF transgene expression and no phenotype. The addition of doxycycline to the drinking water resulted in prominent transgene expression and evidence of neovascularization within 3 to 4 days. Like rho/VEGF mice, the neovascularization originated from the deep capillary bed of the retina, but it was more extensive and caused outer retinal folds followed by total retinal detachment. Real-time polymerase chain reaction and enzyme-linked immunosorbent assay demonstrated that the mice with inducible expression of VEGF that developed retinal detachment had much higher ocular levels of VEGF mRNA and protein compared to rho/VEGF mice that manifest a much milder phenotype. These data demonstrate that regardless of developmental stage of the vascular bed, increased expression of VEGF in the retina is sufficient to cause neovascularization, and high levels of expression cause severe neovascularization and traction retinal detachment. Mice with inducible expression of VEGF in the retina provide a valuable new model of ocular neovascularization.
AB - Transgenic mice with vascular endothelial growth factor (VEGF) driven by the rhodopsin promoter (rho/VEGF mice) develop neovascularization that originates from the deep capillary bed of the retina and grows into the subretinal space. In rho/VEGF mice, VEGF expression in photoreceptors begins between postnatal days 5 and 7, the period when the deep capillary bed is developing. An important question is whether or not the developmental stage of the deep capillary bed is critical for occurrence of neovascularization. Also, although rho/VEGF mice are extremely useful for the study of ocular neovascularization, there are some applications for which the early onset of VEGF expression is a disadvantage. In this study, we used the reverse tetracycline transactivator (rtTA) inducible promoter system coupled to either the rhodopsin or interphotoreceptor retinoid-binding protein (IRBP) promoter to control the time of onset of VEGF transgene expression in photoreceptors. In the absence of doxycycline, adult double-transgenic rho/rtTA-TRE/VEGF or IRBP/rtTA-TRE/VEGF mice showed little VEGF transgene expression and no phenotype. The addition of doxycycline to the drinking water resulted in prominent transgene expression and evidence of neovascularization within 3 to 4 days. Like rho/VEGF mice, the neovascularization originated from the deep capillary bed of the retina, but it was more extensive and caused outer retinal folds followed by total retinal detachment. Real-time polymerase chain reaction and enzyme-linked immunosorbent assay demonstrated that the mice with inducible expression of VEGF that developed retinal detachment had much higher ocular levels of VEGF mRNA and protein compared to rho/VEGF mice that manifest a much milder phenotype. These data demonstrate that regardless of developmental stage of the vascular bed, increased expression of VEGF in the retina is sufficient to cause neovascularization, and high levels of expression cause severe neovascularization and traction retinal detachment. Mice with inducible expression of VEGF in the retina provide a valuable new model of ocular neovascularization.
UR - http://www.scopus.com/inward/record.url?scp=0036168483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036168483&partnerID=8YFLogxK
U2 - 10.1016/S0002-9440(10)64891-2
DO - 10.1016/S0002-9440(10)64891-2
M3 - Article
C2 - 11839592
AN - SCOPUS:0036168483
SN - 0002-9440
VL - 160
SP - 711
EP - 719
JO - American Journal of Pathology
JF - American Journal of Pathology
IS - 2
ER -